Drug Profile
RMC 035
Alternative Names: A1M-001; Alfa-1-Mikroglobulin - Guard Therapeutics; Alpha-1-microglobulin - Guard Therapeutics; RMC-035; ROSgard; α1-microglobulin - Guard TherapeuticsLatest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator A1M Pharma AB
- Developer Guard Therapeutics
- Class Antihypertensives; Radioprotectives; Recombinant proteins; Urologics
- Mechanism of Action Alpha 1 microglobulin replacements; Antioxidants; Free radical scavengers; Haemoglobin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute kidney injury
- No development reported Preeclampsia; Radiation injuries
Most Recent Events
- 23 Jan 2024 Guard Therapeutics receives a positive feedback from the US FDA for RMC 035 in Acute kidney injury
- 23 Jan 2024 Guard Therapeutics completes the phase I AKITA trial for Acute kidney injury (Prevention, In adults, In the elderly) in US, Canada, Germany, Czech Republic and Spain (IV) (NCT05126303)
- 18 Jan 2024 Guard Therapeutics plans a phase IIb POINTER trial for Acute kidney injury in the third quarter of 2024